BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance.

Abstract

The efficacy of selective BRAF inhibitors has now been established in the 50% of patients with metastatic melanoma whose tumors harbor activating mutations. However, for the vast majority of patients, responses persist for less than a year. In extensive preclinical investigations, researchers have focused on potential resistance mechanisms with the hope of… (More)
DOI: 10.1158/1078-0432.CCR-11-0997

Topics

3 Figures and Tables

Cite this paper

@article{Alcal2012BRAFIF, title={BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance.}, author={Alexander Marzuka Alcal{\'a} and Keith T. Flaherty}, journal={Clinical cancer research : an official journal of the American Association for Cancer Research}, year={2012}, volume={18 1}, pages={33-9} }